Canntab Therapeutics Valuation
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Canntab Therapeutics from analyzing the firm fundamentals such as Return On Equity of -6.02, operating margin of (26.95) %, and Shares Outstanding of 38.91 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Canntab Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Canntab Therapeutics is based on 3 months time horizon. Increasing Canntab Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Canntab pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Canntab Therapeutics Limited. Since Canntab Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Canntab Pink Sheet. However, Canntab Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The real value of Canntab Pink Sheet, also known as its intrinsic value, is the underlying worth of Canntab Therapeutics Company, which is reflected in its stock price. It is based on Canntab Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Canntab Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Canntab Therapeutics Limited helps investors to forecast how Canntab pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Canntab Therapeutics more accurately as focusing exclusively on Canntab Therapeutics' fundamentals will not take into account other important factors: Canntab Therapeutics Total Value Analysis
Canntab Therapeutics Limited is currently forecasted to have takeover price of 1.73 M with market capitalization of 774.29 K, debt of 126.2 K, and cash on hands of 691.11 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Canntab Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.73 M | 774.29 K | 126.2 K | 691.11 K |
Canntab Therapeutics Investor Information
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.1. Canntab Therapeutics last dividend was issued on the 8th of March 2016. The entity had 1:200 split on the 20th of April 2018. Based on the key indicators related to Canntab Therapeutics' liquidity, profitability, solvency, and operating efficiency, Canntab Therapeutics Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Canntab Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Canntab Therapeutics has an asset utilization ratio of 10.29 percent. This implies that the Company is making $0.1 for each dollar of assets. An increasing asset utilization means that Canntab Therapeutics Limited is more efficient with each dollar of assets it utilizes for everyday operations.Canntab Therapeutics Ownership Allocation
Canntab Therapeutics holds a total of 38.91 Million outstanding shares. Canntab Therapeutics Limited shows 15.08 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Canntab Therapeutics Profitability Analysis
The company reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Canntab Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Canntab Therapeutics and how it compares across the competition.
About Canntab Therapeutics Valuation
The pink sheet valuation mechanism determines Canntab Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Canntab Therapeutics. We calculate exposure to Canntab Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Canntab Therapeutics's related companies.Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.
8 Steps to conduct Canntab Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Canntab Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Canntab Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Canntab Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Canntab Therapeutics' revenue streams: Identify Canntab Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Canntab Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Canntab Therapeutics' growth potential: Evaluate Canntab Therapeutics' management, business model, and growth potential.
- Determine Canntab Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Canntab Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Canntab Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Canntab Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.9 M | |
| Retained Earnings | -16.7 M |
Complementary Tools for Canntab Pink Sheet analysis
When running Canntab Therapeutics' price analysis, check to measure Canntab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canntab Therapeutics is operating at the current time. Most of Canntab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Canntab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canntab Therapeutics' price. Additionally, you may evaluate how the addition of Canntab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |